A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.

Marberger, Michael; Chartier-Kastler, Emmanuel; Egerdie, Blair; Lee, Kyu-Sung; Grosse, Joachim; Bugarin, Denise; Zhou, Jihao; Patel, Anand; Haag-Molkenteller, Cornelia

Marberger, Michael; Chartier-Kastler, Emmanuel; Egerdie, Blair; Lee, Kyu-Sung; Grosse, Joachim; Bugarin, Denise; Zhou, Jihao; Patel, Anand; Haag-Molkenteller, Cornelia.

Affiliation

Marberger M; Medical University of Vienna, Vienna, Austria. michael.marberger@A1.net

Eur Urol ; 63(3): 496-503, 2013 Mar.

Article in En | MEDLINE | ID: mdl-23098762

Subject(s)

Botulinum Toxins, Type A/administration & dosage; Lower Urinary Tract Symptoms/drug therapy; Neuromuscular Agents/administration & dosage; Prostatic Hyperplasia/drug therapy; Aged; Botulinum Toxins, Type A/adverse effects; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Injections, Intralesional; Lower Urinary Tract Symptoms/etiology; Male; Middle Aged; Neuromuscular Agents/adverse effects; Placebos; Prostatic Hyperplasia/complications; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Hyperplasia / Botulinum Toxins, Type A / Lower Urinary Tract Symptoms / Neuromuscular Agents Type of study: Clinical_trials / Etiology_studies Limits: Aged / Humans / Male / Middle aged Language: En Journal: Eur Urol Year: 2013 Type: Article Affiliation country: Austria

Fulltext

XML

PubMed Links

Search on Google